Among patients with pulmonary alveolar proteinosis, treatment with daily inhaled recombinant human granulocyte-macrophage colony-stimulating factor, or sargramostim, was associated with a modest ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, ...
Extract: Serial studies of arterial and alveolar oxygen, carbon dioxide, and nitrogen tensions, arterial pH, and ratios of dead space: tidal volume were made in 24 nondistressed premature infants. By ...
The safety and efficacy of Molgradex was evaluated in a double blind, placebo controlled trial involving 138 patients with aPAP. Savara Inc. announced topline data from the pivotal phase 3 trial, ...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in ...
Savara's Molgramostim, a GM-CSF therapy, succeeded in a phase 3 trial for treating aPAP, a rare autoimmune lung condition, after a previous failure. The current standard treatment, WLL, is effective ...
-- Real World, Retrospective Outcomes Data Suggest Molgramostim Addresses the Underlying Pathophysiology of aPAP Resulting in Improved Lung Function, Decreased Disease Burden, Restored Patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback